{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:57:48Z","timestamp":1762865868371,"version":"3.40.4"},"reference-count":10,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Quinolones are used extensively for prophylaxis in high-risk cancer patients; however, increasing quinolone resistance is being reported. Extended-spectrum \u03b2-lactamase (ESBL)-producing &lt;i&gt;E. coli&lt;\/i&gt; may be associated with increased morbidity and mortality particularly in neutropenic cancer patients. &lt;i&gt;Methods:&lt;\/i&gt; We conducted a retrospective study of consecutive &lt;i&gt;E. coli&lt;\/i&gt; isolates from January 2009 to August 2009 at our institution. Data on antimicrobial susceptibility of &lt;i&gt;E. coli&lt;\/i&gt; isolates to commonly used antimicrobial agents and the frequency of ESBL production and fluoroquinolone resistance were gathered based on CLSI guidelines. &lt;i&gt;Results:&lt;\/i&gt; There were 443 isolates of &lt;i&gt;E. coli&lt;\/i&gt; recovered. The majority were from urine cultures (308 isolates, 69.5%). Forty-one (9.2%) isolates were ESBL producing. Nine (18.3%) of the 49 isolates recovered from blood stream infections were ESBL producing. Quinolone resistance was present in 204 isolates (46%). Carbapenems and aminoglycosides retained excellent activity. &lt;i&gt;E. coli&lt;\/i&gt; resistance to quinolones increasedfrom 13 to 46% in a period of 13 years (p = 0.001). &lt;i&gt;Conclusion:&lt;\/i&gt; The incidence of resistance to quinolones at our center may be increasing as a consequence of widespread use of quinolones as prophylaxis for neutropenic patients. ESBL-producing &lt;i&gt;E. coli&lt;\/i&gt; are frequent at our center and are associated with blood stream infections.<\/jats:p>","DOI":"10.1159\/000329661","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T06:49:23Z","timestamp":1315291763000},"page":"335-338","source":"Crossref","is-referenced-by-count":33,"title":["Incidence of Fluoroquinolone-Resistant and Extended-Spectrum \u03b2-Lactamase-Producing&lt;i&gt; Escherichia coli&lt;\/i&gt; at a Comprehensive Cancer Center in the United States"],"prefix":"10.1159","volume":"57","author":[{"given":"Y.","family":"Bhusal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.N.","family":"Mihu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Tarrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.V.","family":"Rolston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,9,6]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1086%2F520247"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1056%2FNEJMoa044097"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1086%2F422647"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1093%2Fjac%2Fdkm514"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1159%2F000321018"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1159%2F000007223"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1002%2Fcncr.24812"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1016%2Fj.diagmicrobio.2010.02.014"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1159%2F000224657"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1086%2F374339"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329661","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:21:49Z","timestamp":1745432509000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000329661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,9,1]]},"published-print":{"date-parts":[[2011,9,20]]}},"URL":"https:\/\/doi.org\/10.1159\/000329661","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2011]]}}}